AN EXPLORATION OF THE PSYCHEDELICS ECOSYSTEM

AN EXPLORATION OF THE PSYCHEDELICS ECOSYSTEM

June 15th, 2020

Caitlin Thompson

Monday, June 15th
9:30 AM ET
Psychedelics as a Novel Approach to Autoimmune Conditions.

After conquering her own battle with depression and anxiety, neurobiologist Caitlin Thompson set out on a mission to share healing tools and empower other individuals to take their mental wellness into their own hands. During her healing process from Lyme disease, chronic fatigue, PTSD, pain, and a plethora of other autoimmune symptoms, she founded her nutritional supplement company, EntheoZen in an effort to bring the importance of nutrient therapy into light in regards to mood health. She is also a practicing medicine woman and is a certified Kambo practitioner. Caitlin is an independent scientific researcher and is conducting research on the potential of psychedelic compounds as a novel approach to autoimmune conditions, as well as the first human kambo studies. Her greatest passion is sharing her healing journey and using it to inspire and empower others with the knowledge that everyone has the innate ability to heal themselves.

Jerry B. Brown, PhD

Monday, June 15th
10 AM ET
Mystical Experience and Psychedelic-Assisted Psychotherapy

Jerry B. Brown is an anthropologist and Julie M. Brown is a psychotherapist. They coauthored The Psychedelic Gospels: The Secret History of Hallucinogens in Christianity, 2016.The Johns Hopkins and NYU studies of the impact of psilocybin on cancer patients found that “In both trials, the intensity of the mystical experience described by patients correlated with the degree to which their depression and anxiety decreased.” In other words, research scientists have consistently occasioned mystical experiences ̶ “flights of the soul” traditionally thought to be beyond the scope of empirical science ̶ in clinical settings by administering high-dose synthetic psilocybin. Furthermore, it turns out that these experiences hold the key to positive patient outcomes in psychedelic-assisted psychotherapy. This presentation explores the role of mystical experience in psychedelic-assisted psychotherapy and in psychotherapy using guided imagery.

Adam Knowles

Monday, June 15th
10:30 AM ET

Adam is an existential psychotherapist researching the Amazonian plant medicine ayahuasca and its potential to help those in the UK with insight and well-being. Learn more at ayaresearch.com

SPONSORSHIP

Martina Hoffman

Monday, June 15th
11:30 PM ET
Art and the Inner Journey as Tools for Transformation

Martina’s art explores the mysterious and essential nature of consciousness as it exists in all living things and is expressed as energy. Her ‘Visionary Symbolism’ is decidedly feminine and places the archetype of the ‘Universal Woman’ in an intimate cosmos. She translates her experiences as well as her reflections on our place in the universe in a symbolic style which marries the fantastic to the sacred. Martina Hoffmann has spoken at symposiums and festivals about visionary art and culture worldwide.

Kim Kuypers

Monday, June 15th
12 PM ET

Kim PC Kuypers (PhD) is affiliated as an Associate Professor with Maastricht University, Faculty of Psychology and Neuroscience where she obtained her PhD in 2003. Her main goal is to understand the neurobiology underlying flexible cognition, empathy and well-being. To accomplish this she uses a psychopharmacological model, to induce (sub)acute and longer lasting effects on aforementioned behavior with psychedelics, and investigate the underlying biology. She also conducts survey research to understand the motives underlying psychedelic use, and the experienced effects, and she develops new paradigms to study cognitive flexibility and empathy in a more ecologically valid way. The survey research gives direction to her experimental research in which she uses the newly developed paradigms. Her research contributes to the understanding of the biological and psychological underpinnings of cognitive and emotional processes linked to well-being.

Brian Earp

Monday, June 15th
12:30 PM ET

Brian is co-author of the book Love Drugs: The Chemical Future of Relationships (Stanford University Press, 2020; published in the UK by Manchester University Press as Love Is the Drug: The Chemical Future of Our Relationships). The book calls for a "relational turn" in research on the therapeutic effects of MDMA and psychedelic drugs including psilocybin, asking how drug-assisted psychotherapy could benefit couples. Brian is Associate Director of the Yale-Hastings Program in Ethics and Health Policy at Yale University and The Hastings Center, and a Research Fellow in the Uehiro Centre for Practical Ethics at the University of Oxford. His work is cross-disciplinary, following training in philosophy, cognitive science, psychology, history and sociology of science and medicine, and ethics. Brian is co-recipient of the 2018 Daniel M. Wegner Theoretical Innovation Prize from the Society for Personality and Social Psychology. He is also recipient of both the Robert G. Crowder Prize in Psychology and the Ledyard Cogswell Award for Citizenship from Yale University, where he was elected President of the Yale Philosophy Society as an undergraduate as well as Editor-in-Chief of the Yale Philosophy Review. He then conducted graduate research in psychological methods as a Henry Fellow of New College at the University of Oxford. He also conducted graduate research in the history, philosophy, and sociology of science, technology, and medicine as a Cambridge Trust Scholar and Rausing Award recipient at Trinity College at the University of Cambridge. After spending a year in residence as the inaugural Presidential Scholar in Bioethics at The Hastings Center in Garrison, New York, Brian is now a Benjamin Franklin Resident Graduate Fellow at Yale University, where he is finishing his Ph.D. in philosophy and psychology, having been jointly admitted to both departments. His essays have been translated into Polish, German, Italian, Spanish, French, Portuguese, and Hebrew.

Rotem Petranker

Monday, June 15th
1 PM ET

Rotem Petranker is a clinical psychology PhD student at York University, and is the Associate Director of Center for Psychedelic Studies at the University of Toronto.

Rick Strassman

Monday, June 15th
1:30 PM ET
Psychedelics for Everything: Panacea, placebo, or too good to be true?

Rick Strassman is a professor of psyciatry and regularly published for his clinial reasearch. He is the author of the book DMT: The Spirit Molecule, covering his experimental studies and academic research into DMT, which was made into a documentary film in 2010.

Dana Beal

Monday, June 15th
2:30 PM ET

Dana Beal, Yippie! heir to Wm. Burroughs & Allen Ginsberg who re-initiated ibogaine development with Howard Lotsof in the December of 1980, is the principal champion of Robert Gouterel's hypothesis identifying ibogaine mechanism with the neural plasticity of REM sleep, as opposed to the NIDA's reduction of ibogaine effect to blockade of a single alpha 3 beta 4 nicotinic acetyl-choline receptor. In "THE IBOGAINE STORY: Report on the Staten Island Project," Beal was the first to correlate ibogaine visualizations with the Penrose/Hameroff hypothesis of a photonic basis of consciousness in the microtubules of neurons, correctly intuiting that the “neuro-plastic“ function neurotrophins play in correcting longterm memory (Woolfe, 1998) heralded the findings of Ron, et al. in 2005-6—of a role for nerve growth factors such as GDNF in ibogaine’s persistent effect. In 2014 that led him to predict (correctly) that ibogaine would be effective for Parkinson’s disease. In Feb 2016, he issued an impassioned call during UNGASS for the countries of the World not to reflexively schedule ibogaine in the midst of a world opiate/methamphetamine crisis on account of the U.S. ban.

Matthew Johnson

Monday, June 15th
3 PM ET
Therapeutic Effects of Psilocybin

Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. He is one of the world’s most published scientists on the human effects of psychedelics. Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004, and has published >120 peer-reviewed articles. Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule-IV upon potential medical approval. He is Principle Investigator on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD, and LSD in the treatment of chronic pain. In psychedelic research he also published the first blinded research showing effects of salvinorin A, and research examining psychedelic effects on mystical experience, personality change, meditation, and naturalistic addiction recovery. Dr. Johnson is also known for his behavioral economics research, including decision-making underlying addiction, tobacco regulatory science, and drug effects on sexual risk behavior. He has published studies on nearly all psychoactive drug classes. Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and is the 2020-2021 President of the International Society for Research on Psychedelics. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for >75 journals and has served as guest editor on special issues on psychedelics in two peer-reviewed journals. Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the USA. He has provided invited presentations in 13 nations. Dr. Johnson has been interviewed widely including by Anderson Cooper on 60 Minutes, Fox Business News, CNN, NPR, BBC, New York Times, Washington Post, Wall Street Journal, and Michael Pollan.

Alex Speiser

Monday, June 15th
3:30 PM ET

COO of Orthogonal Thinker, a plant medicine platform dedicated to individual and collective well-being via psychoactive compounds and clean label products. Speiser is an early-stage startup investor with a track record of successful ventures and strategic roles including V.P. of Business Development of G.S. Power Partners. He received a B.A. with Honors in the College of Social Studies and the College of the Environment from Wesleyan University.

Adele Lafrance & Reid Robison

Monday, June 15th
4 PM ET
Part 1: The good, the bad, & the ugly: contraindications, optimal conditions & psychospiritual emergencies in psychedelic medicine

Adele Lafrance, PhD, is clinical psychologist, research scientist, and co-developer of Emotion-Focused Family Therapy. She is also a leader in the research and practice of psychedelic medicine for eating disorders.

Reid Robison & Adele Lafrance

Monday, June 15th
4:30 PM ET
Part 2: Safety considerations & prohibited medications for psychedelic experiences: What does the science say?

Reid Robison MD MBA is a board certified psychiatrist who has led over 100 clinical trials. He is founder & medical director at Cedar Psychiatry and serves as coordinating investigator for the MAPS MDMA-assisted psychotherapy study of eating disorders. Reid often consults on medical safety issues in psychedelic medicine use. Adele Lafrance, PhD, is clinical psychologist, research scientist, and co-developer of Emotion-Focused Family Therapy. She is also a leader in the research and practice of psychedelic medicine for eating disorders.

Copter Ruangrojanin

Monday, June 15th
5 PM ET
Fraqtal: The Need for Comprehensive Industry Analysis of the Psychedelics Ecosystem

Copter is a venture capital professional. He has worked across different startup ecosystems, ranging from fintech to transportation platform. A scientist by training, he is passionate and interested in the biological processes of psychedelics and its therapeutics benefits.